These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19922755)

  • 1. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?
    Deng C; Weston-Green K; Huang XF
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):1-4. PubMed ID: 19922755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: The roles in olanzapine-induced obesity.
    He M; Zhang Q; Deng C; Jin T; Song X; Wang H; Huang XF
    Psychoneuroendocrinology; 2017 Nov; 85():190-199. PubMed ID: 28886461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
    Kroeze WK; Hufeisen SJ; Popadak BA; Renock SM; Steinberg S; Ernsberger P; Jayathilake K; Meltzer HY; Roth BL
    Neuropsychopharmacology; 2003 Mar; 28(3):519-26. PubMed ID: 12629531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
    Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL
    J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.
    Lian J; Huang XF; Pai N; Deng C
    Pharmacol Res; 2016 Apr; 106():51-63. PubMed ID: 26892184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
    Reynolds GP; Kirk SL
    Pharmacol Ther; 2010 Jan; 125(1):169-79. PubMed ID: 19931306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
    Han M; Deng C; Burne TH; Newell KA; Huang XF
    Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible involvement of serotonin 5-HT2 receptor in the regulation of feeding behavior through the histaminergic system.
    Murotani T; Ishizuka T; Isogawa Y; Karashima M; Yamatodani A
    Neuropharmacology; 2011; 61(1-2):228-33. PubMed ID: 21514311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight.
    Malmlöf K; Zaragoza F; Golozoubova V; Refsgaard HH; Cremers T; Raun K; Wulff BS; Johansen PB; Westerink B; Rimvall K
    Int J Obes (Lond); 2005 Dec; 29(12):1402-12. PubMed ID: 16151415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Weight gain from atypical neuroleptics--an underreported adverse effect?].
    Wetterling T
    Fortschr Neurol Psychiatr; 2000 Dec; 68(12):546-56. PubMed ID: 11200858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
    Lian J; Huang XF; Pai N; Deng C
    Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histamine H3 receptor and eating behavior.
    Passani MB; Blandina P; Torrealba F
    J Pharmacol Exp Ther; 2011 Jan; 336(1):24-9. PubMed ID: 20864503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
    Deng C; Lian J; Pai N; Huang XF
    J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics and weight gain.
    Postgrad Med; 2003 Dec; 114(6 Suppl Managing Metabolic):46-58. PubMed ID: 19667655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.
    He M; Deng C; Huang XF
    CNS Drugs; 2013 Jun; 27(6):423-34. PubMed ID: 23640535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain.
    Tiwari AK; Zhang D; Pouget JG; Zai CC; Chowdhury NI; Brandl EJ; Qin L; Freeman N; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
    World J Biol Psychiatry; 2018; 19(sup3):S97-S105. PubMed ID: 27855565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histamine H3-receptor inverse agonists as novel antipsychotics.
    Ito C
    Cent Nerv Syst Agents Med Chem; 2009 Jun; 9(2):132-6. PubMed ID: 20021346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways.
    Lian J; De Santis M; He M; Deng C
    Pharmacol Res; 2015; 95-96():20-6. PubMed ID: 25782398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
    Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
    Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.